Eli Lilly inaugurates R&D facility in Boston
by 
Eli Lilly and Company has opened the Lilly Seaport Innovation Center (LSC), a research and development (R&D) hub in the Seaport district of Boston, US. The centre is set to progress the company’s work on RNA and DNA-based therapies and discover new drug targets for diabetes, obesity and cardiovascular issues. It is designed to accommodate 500 Lilly scientists and researchers.
Lilly Research Laboratories chief scientific officer and president, and Lilly immunology president Daniel Skovronsky stated: “The opening of LSC expands upon Lilly’s long-standing presence in the Boston area. “We are committed to being supportive neighbors in this hub of discovery and innovation, further collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them most.”
LSC occupies 346,000 square feet in a 12-story building, developed and operated by Alexandria Real Estate Equities, Inc. (ARE), in the rapidly expanding Seaport district of Boston. The new site includes laboratories and office space and will also house the first Lilly Gateway Labs location on the East Coast, fostering a culture of shared expertise and real-time learning to accelerate the development of novel medicines. LSC will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from the companies within Lilly Gateway Labs.
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/